Thursday, July 5th, 2018
Monitoring for Recurrent and Second Cancers
Although active cancer treatment is behind you, it is possible the cancer may recur (come back) or that a new type of cancer (second cancer) may develop. Both of these possibilities make it critical for you to stay on top of your health by adhering to your follow-up plan.
When cancer that’s the same type as the original cancer comes back, it’s called recurrent cancer. If you are cancer-free after being treated for a specific type of lung cancer and, a few years later, you are again diagnosed with that same type of lung cancer, that it is recurrent cancer. It can happen weeks, months or even years after treatment stops, and cancer may come back in the same area of the body as the primary cancer (local recurrence), in an area of the body near the location of the primary cancer (regional recurrence), or in an altogether different area of the body (distant recurrence).
Cancer sometimes comes back because tiny cancer cells occasionally survive treatment and remain in the body undetected. These lingering cells grow and multiply until, eventually, tests can detect them.
Although doctors cannot know for sure who will experience cancer recurrence, they can sometimes make predictions based on the recurrence patterns of certain cancers. Be sure to ask your doctor for more information about your recurrence risk profile.
Like recurrent cancer, a second cancer can develop after you’ve finished treatment for the first cancer. However, unlike recurrent cancer, a second cancer is a different or new type of cancer diagnosis. For example, you are cancer-free after being treated for ovarian cancer and then, a few years later, you are diagnosed with breast cancer. The breast cancer is considered a second cancer.
Many factors are linked to the development of a second cancer.
- Cancer treatments. Leukemia and some solid tumors have been linked to past radiation exposure and past chemotherapy.
- Cancer types. Although it’s not yet clear if second cancers are caused by the original cancer or its treatment (or a combination of the two), some primary cancer types are associated with certain second cancers (see Table 1).
- Inherited and/or acquired gene mutations. When certain genes mutate due to inherited syndromes (passed down from generation to generation) or acquired circumstances (changes that arise throughout a person’s lifetime), the risk for various cancer types increases (see Genetic Testing).
- Personal characteristics. Age (both current and at the time of primary treatment), gender, race, ethnicity and health status are among the personal characteristics that can play a role in your risk for developing a second cancer.
- Lifestyle choices. Various unhealthy choices, including poor diet, physical inactivity, smoking and excessive alcohol use, might increase the chance of a second cancer.
The risk for developing a second cancer is small, but it’s still important to talk to your doctor about what to look for and what you can do to help minimize your risk.
|Primary Cancer||Commonly Associated Second Cancers*|
|Bladder||Bladder**, Colon, Lung, Prostate|
|Breast||Breast (female, opposite side)**, Colon, Lung, Ovarian, Uterine|
|Colon||Bladder, Breast (female), Colorectal**, Lung, Non-Hodgkin Lymphoma, Prostate|
|Hodgkin Lymphoma||Acute Non-Lymphocytic Leukemia (ANLL), Breast (female), Colon, Lung, Non-Hodgkin Lymphoma, Prostate|
|Testicular||Bladder, Lung, Prostate|
Monitoring Your Health
As a part of your follow-up care plan, your doctor will watch for a potential recurrence or second cancer. Your plan might include physical examinations, blood tests, imaging tests and/or scheduled cancer screenings.
The National Comprehensive Cancer Network recommends certain screening guidelines for most adults by cancer type (see Table 2). However, variations and exceptions to these rules exist, so talk to your doctor about the schedule that’s right for you.
Along with getting screened at the recommended times, you can also be an active participant in monitoring your health. For example, most recurrences of melanoma develop within the first five years after treatment, so your follow-up visits will be more frequent within that time period. However, late recurrence, even after 10 years, is also possible. Your doctor will ask you to participate in your follow-up care with a monthly self-examination of your skin for potential melanoma. During these skin checks, you should also look for any abnormal lumps, especially where the surgery was done, if applicable, and in nearby lymph nodes. The “ABCDE” rule will help you know the difference between melanoma and a mole that is benign (noncancerous) (see Figure 1). Because family history plays an important role in melanoma and other skin cancers, your family members should also have regular skin screenings.
If cancer is detected, your doctor will run various diagnostic tests to learn as much as possible and will then talk with you about your treatment options.
|Cancer Type||Screening Test||Age||Frequency|
|Breast cancer||Breast self-exam (BSE)||20+ (women)||Regularly|
|Clinical breast exam (CBE)||40+ (women)||Yearly|
|Cervical cancer||Pap test||21 to 29 (women)||Every 3 years|
|Pap test + human papillomavirus (HPV) test||30 to 65 (women)||Every 5 years|
|Colorectal cancer||Colonoscopy||50+ (men and women)||Every 10 years|
|Lung cancer||Low-dose computed tomography (LDCT) of the chest||55 to 74 (men and women)*||Yearly|
|Prostate cancer||Prostate-specific antigen (PSA) blood test with or without a digital rectal exam (DRE)||50 to 70 (men)**||Varies based on PSA level|
Taken from www.patientresource.com/Survivorship_Recurrence.aspx
Tuesday, July 3rd, 2018
Our office will be closed on Wednesday, July 4, 2018.
We wish every one a safe and happy holiday!
NRG Oncology’s GOG-0218 Trial Leads to FDA Approval of Chemotherapy with Bevacizumab for Women with Ovarian Cancer Following Initial Surgery
Tuesday, June 26th, 2018
Thank you to our patients who participated in this clinical trial!
PHILADELPHIA, PA —The U.S. Food and Drug Administration (FDA) recently approved the use of bevacizumab (Avastin®) in combination with carboplatin and paclitaxel followed by Avastin as a single agent, as a treatment for women with advanced stage III or IV ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. The FDA approval stems from the results of the double blind, placebo-controlled, phase 3 NRG Oncology trial GOG-0218, which revealed the addition of bevacizumab improved progression-free survival (PFS) for women when compared to chemotherapy alone. GOG-0218 was conducted by the Gynecologic Oncology Group (GOG, now part of NRG Oncology) and sponsored by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) under its Cooperative Research and Development Agreement with Genentech, a member of the Roche Group, for bevacizumab.
Read the full press release here.
Sunday, June 10th, 2018
Immuno-oncology is the study and development of treatments for cancer that take advantage of the body’s own immune system.
Monday, June 4th, 2018